State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa Macao SAR, China.
Shenzhen People's Hospital, Shenzhen, Guangdong 518000, China.
Anal Chem. 2024 Aug 20;96(33):13576-13587. doi: 10.1021/acs.analchem.4c02339. Epub 2024 Aug 5.
Glucuronidation, a crucial process in phase II metabolism, plays a vital role in the detoxification and elimination of endogenous substances and xenobiotics. A comprehensive and confident profiling of glucuronate-conjugated metabolites is imperative to understanding their roles in physiological and pathological processes. In this study, a chemical isotope labeling and dual-filtering strategy was developed for global profiling of glucuronide metabolites in biological samples. ,-Dimethyl ethylenediamine (DMED-) and its deuterated counterpart DMED- were used to label carboxylic acids through an amidation reaction. First, carboxyl-containing compounds were extracted based on a characteristic mass difference (Δ/, 6.037 Da) observed in MS between light- and heavy-labeled metabolites (filter I). Subsequently, within the pool of carboxyl-containing compounds, glucuronides were identified using two pairs of diagnostic ions (/ 247.1294/253.1665 and 229.1188/235.1559 for DMED-/DMED--labeled glucuronides) originating from the fragmentation of the derivatized glucuronic acid group in MS/MS (filter II). Compared with non-derivatization, DEMD labeling significantly enhanced the detection sensitivity of glucuronides, as evidenced by a 3- to 55-fold decrease in limits of detection for representative standards. The strategy was applied to profiling glucuronide metabolites in urine samples from colorectal cancer (CRC) patients. A total of 685 features were screened as potential glucuronides, among which 181 were annotated, mainly including glucuronides derived from lipids, organic oxygen, and phenylpropanoids. Enzymatic biosynthesis was employed to accurately identify unknown glucuronides without standards, demonstrating the reliability of the dual-filtering strategy. Our strategy exhibits great potential for profiling the glucuronide metabolome with high coverage and confidence to reveal changes in CRC and other diseases.
糖基化,一种重要的 II 相代谢过程,在解毒和消除内源性物质和外源性物质方面发挥着至关重要的作用。全面而有信心地描绘糖基化缀合物代谢物的图谱对于理解它们在生理和病理过程中的作用至关重要。在这项研究中,开发了一种化学同位素标记和双过滤策略,用于生物样品中糖基化代谢物的全局分析。通过酰胺化反应,使用二甲基乙二胺(DMED-)及其氘代物 DMED-来标记羧酸。首先,根据轻标记和重标记代谢物之间在 MS 中观察到的特征质量差异(Δ/,6.037 Da)提取含有羧基的化合物(过滤 I)。随后,在含有羧基的化合物池中,使用两对来自衍生化的葡萄糖醛酸基团在 MS/MS 中产生的诊断离子(/ 247.1294/253.1665 和 229.1188/235.1559 对 DMED-/DMED--标记的糖基化产物进行鉴定(过滤 II)。与非衍生化相比,DEMD 标记显著提高了糖基化物的检测灵敏度,代表性标准的检测限降低了 3 到 55 倍。该策略应用于结直肠癌(CRC)患者尿液样本中糖基化代谢物的分析。共筛选出 685 种潜在的糖基化产物,其中 181 种被注释,主要包括脂质、有机氧和苯丙素衍生的糖基化产物。利用酶促生物合成方法在没有标准品的情况下准确鉴定未知糖基化产物,证明了双过滤策略的可靠性。我们的策略具有很高的覆盖度和置信度来描绘糖基化代谢组,以揭示 CRC 和其他疾病的变化潜力。